QPPV.COM KNOWLEDGE ASSESSMENT

Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making

Test your understanding of the concepts covered by Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement correctly describes the relationship between the original MRP or DCP dossier and the Article 29(4) assessment?

The referral is a completely new marketing authorisation application submitted to EMA The original assessment is irrelevant once CHMP becomes involved The referral escalates an existing disagreement, with the original assessment and referral documentation forming part of the evidentiary history Only information generated after the referral may be considered

Question 2 of 10 What is the key operational distinction between the initial 15-day re-examination notification and the 60-day detailed grounds?

The first is the formal intention to seek re-examination; the second explains the substantive grounds for challenging the opinion The first contains new data; the second is only an administrative acknowledgement The first is submitted to the Commission; the second is submitted to CMDh The first applies only to safety issues; the second applies only to efficacy issues

Question 3 of 10 Which implementation activity is most directly required after a Commission decision changes safety wording for nationally authorised products?

Wait for a new PRAC referral before changing national product information Implement the final wording and associated requirements through the applicable national-authorisation framework, with controlled translation and documentation Replace the Commission decision with the company's preferred wording Update only the global safety database and take no regulatory action

Question 4 of 10 What is the most defensible way to assess whether an Article 29(4) outcome requires an RMP update?

Update the RMP automatically whenever any Article 29(4) referral occurs Never update the RMP because the referral is a regulatory rather than PV procedure Assess whether the final decision changes the safety specification, risk characterisation, missing information or required risk-management activities Update the RMP only when the Commission decision revokes the authorisation

Question 5 of 10 A CMS disagrees with the RMS assessment during a DCP but the concern does not meet the potential serious risk to public health threshold. What is the most appropriate interpretation?

An Article 29(4) referral is automatically required because any CMS disagreement qualifies The issue should be referred directly to PRAC The disagreement does not, on the information given, qualify for Article 29(4) The European Commission must immediately adopt a binding decision

Question 6 of 10 Which chronology most accurately represents the core Article 29(4) pathway?

PRAC signal assessment, Commission decision, CMS review, CHMP opinion MRP or DCP, RMS assessment, CMS concern, CMDh coordination, RMS referral, CHMP assessment, Commission decision Commission decision, RMS assessment, CMDh coordination, DCP, national implementation EMA safety investigation, PRAC opinion, RMS referral, national authorisation

Question 7 of 10 A company submits a scientifically complete response but receives no acknowledgement of successful electronic submission. What is the most appropriate action?

Assume that the submission was accepted because the documents were complete Wait until the CHMP meeting to confirm receipt Treat the submission as potentially unsuccessful and investigate promptly according to the applicable submission process Send the same response only to the objecting CMS

Question 8 of 10 Which combination best describes the defining prerequisites for an Article 29(4) referral?

A safety signal identified by PRAC involving a centrally authorised medicine An unresolved disagreement during an MRP or DCP based on a potential serious risk to public health Divergent national decisions concerning an already authorised medicinal product An urgent pharmacovigilance concern involving a nationally authorised medicine

Question 9 of 10 Which approach is consistent with the evidentiary limitation at re-examination?

Use re-examination primarily to introduce previously unavailable new data Focus on how evidence already before CHMP was interpreted, weighted or applied Reopen every element of the original dossier regardless of relevance Replace the initial scientific assessment with an entirely new application

Question 10 of 10 Which approach is most appropriate when a marketing authorisation is transferred during an active referral?

Treat the transfer as unrelated to the referral because ownership is the only issue Require the new MAH to reconstruct the procedure without relying on the former MAH's records Manage the transfer as a controlled handover of procedural responsibility, including correspondence, deadlines, submissions, product information and Article 57 status Terminate the referral automatically upon transfer

QPPV.com

Article 29(4) Referral in EU Medicines Regulation: Legal Basis, Procedure and Regulatory Decision-Making

Cookie Settings